Your session is about to expire
← Back to Search
Dubermatinib for Acute Myeloid Leukemia
Study Summary
This trial is studying the best dose of TP-0903 and whether it is more effective when given with azacitidine to treat patients with FLT3 gene mutated acute myeloid leukemia.
- Acute Myeloid Leukemia
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 1 trial • 48 Patients • NCT02038777Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What are some similar studies that have used Dubermatinib in the past?
"33 Dubermatinib trials are currently in Phase 3 with 180 trials active in total. Most of these studies taking place in Saint Louis, Missouri; however, there are 5727 clinical trial sites for Dubermatinib globally."
Are people currently signing up to be a part of this experiment?
"This clinical trial, which was first advertised on November 5th 2020, is still seeking participants according to the latest update on January 4th 2022."
How many patients are a part of this clinical research?
"That is correct. The listing on clinicaltrials.gov says that the trial is still looking for patients. It was first posted on November 5th, 2020 and was last updated on January 4th, 2022. They are aiming to have 80 people total at 1 location."
What goals is this clinical trial hoping to achieve?
"The primary outcome of this study will be the Composite CR rate with partial hematologic recovery (CRh) rate, which will be monitored for up to 5 years post-registration. Secondary outcomes include The Number of patients who proceed to transplant, Incidence of treatment-related adverse events, and Overall survival."
What are the main purposes that Dubermatinib is typically used for?
"Dubermatinib is most often used as a treatment for cancer. Additionally, it can be prescribed to patients struggling with 20-30% blasts, neutropenia and/or thrombocytopenia, and anemia."
Share this study with friends
Copy Link
Messenger